Inactive Instrument

ChemoCentryx, Inc.

Equities

CCXI

US16383L1061

Pharmaceuticals

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from S&P Global BMI Index CI
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from S&P TMI Index CI
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from S&P Biotechnology Select Industry Index CI
Amgen Completes ChemoCentryx Acquisition MT
Chemocentryx, Inc. Announces Executive Changes CI
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from NASDAQ Composite Index CI
Amgen Inc. completed the acquisition of ChemoCentryx, Inc. from a group of shareholders. CI
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from NASDAQ Biotechnology Index CI
Swissmedic OKs ChemoCentryx's Combo Therapy For Rare Blood Vessel Disease MT
Insider Sell: Chemocentryx MT
UK Agency Recommends Tavneos Combo for Treatment of Rare Blood Vessel Disease MT
Biotech stocks pin bounce back hopes on M&A boost RE
Stifel Cuts ChemoCentryx to Hold From Buy, Price Target to $52 From $86 MT
Insider Sell: ChemoCentryx MT
Insider Sell: ChemoCentryx MT
ChemoCentryx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
SVB Securities Downgrades ChemoCentryx to Market Perform From Outperform, Adjusts Price Target to $52 From $64 MT
HC Wainwright Downgrades ChemoCentryx to Neutral From Buy, Adjusts Price Target to $52 From $101 MT
Amgen Signals Additional $100 Million Hit to Revenue From Foreign Exchange Following Volume-Driven Second-Quarter Beat MT
MarketScreener’s World Press Review : August 5, 2022 Our Logo
Canaccord Genuity Downgrades ChemoCentryx to Hold From Buy; Price Target is $52 MT
Healthcare Shares Slip Amid Deal News -- Healthcare Roundup DJ
Amgen 2Q Profit Jumped After Write-Off From 2021 Acquisition DJ
Sector Update: Health Care Stocks Slipping Ahead of Thursday Close MT
Sector Update: Health Care MT
Chart ChemoCentryx, Inc.
More charts
ChemoCentryx, Inc. is an integrated biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. The Company is targeting the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. Its development pipelines include TAVNEOS and Immuno-Oncology. TAVNEOS is for the treatment of severe hidradenitis suppurativa (HS) and seeks to advance TAVNEOS into Phase III clinical development for the treatment of severe HS. The Company's CCX559 is orally-administered investigational inhibitor for programmed death protein 1/programmed death-ligand 1 (PD-1/PD-L1), which is developing for the treatment of various cancers. It markets TAVNEOS (avacopan) as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis associated vasculitis, specifically granulomatosis with polyangiitis and microscopic polyangiitis.
More about the company